AR044302A1 - Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos - Google Patents
Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticosInfo
- Publication number
- AR044302A1 AR044302A1 ARP040101607A AR044302A1 AR 044302 A1 AR044302 A1 AR 044302A1 AR P040101607 A ARP040101607 A AR P040101607A AR 044302 A1 AR044302 A1 AR 044302A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- pharmaceutical containers
- proteins stabilized
- beta
- liquid proteins
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000003996 Interferon-beta Human genes 0.000 abstract 2
- 108090000467 Interferon-beta Proteins 0.000 abstract 2
- 229960001388 interferon-beta Drugs 0.000 abstract 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229930195722 L-methionine Natural products 0.000 abstract 1
- 239000004809 Teflon Substances 0.000 abstract 1
- 229920006362 Teflon® Polymers 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229940044519 poloxamer 188 Drugs 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mechanical Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Un recipiente que comprende un medio de cierre recubierto por un material fluorado inerte y que contiene una composición farmacéutica. En particular, el recipiente comprende un medio de cierre recubierto por TEFLÓN y contiene una formulación de interferón-beta libre de albúmina sérica humana(ASH) que posee la siguiente composición: de 30 a 100 mg/ml del interferón-beta, un agente de isotonicidad, de 0,1 a 2 mg/,ml de Poloxamer 188, al menos 0,12 mg/ml de L-metionina y una solución tampón capaz de mantener el pH de la formulación líquida a un valor de entre 3,0 y 4,0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03010671 | 2003-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044302A1 true AR044302A1 (es) | 2005-09-07 |
Family
ID=33442722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101607 AR044302A1 (es) | 2003-05-13 | 2004-05-11 | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | USRE43331E1 (es) |
| EP (2) | EP1633388B1 (es) |
| JP (2) | JP2007502684A (es) |
| KR (1) | KR101084412B1 (es) |
| CN (1) | CN1809376B (es) |
| AR (1) | AR044302A1 (es) |
| AU (1) | AU2004237982C1 (es) |
| BR (1) | BRPI0410679A (es) |
| CA (1) | CA2523477A1 (es) |
| CY (1) | CY1115233T1 (es) |
| DK (1) | DK1633388T3 (es) |
| EA (1) | EA008308B1 (es) |
| ES (1) | ES2471942T3 (es) |
| HR (1) | HRP20140267T1 (es) |
| IL (1) | IL171912A (es) |
| MX (1) | MXPA05012191A (es) |
| NO (1) | NO20055774D0 (es) |
| PL (1) | PL1633388T3 (es) |
| PT (1) | PT1633388E (es) |
| SI (1) | SI1633388T1 (es) |
| UA (1) | UA91493C2 (es) |
| WO (1) | WO2004100979A2 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070012464A (ko) * | 2004-05-17 | 2007-01-25 | 아레스 트레이딩 에스.아. | 하이드로겔 인터페론 제제 |
| CN1993139B (zh) * | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
| CN101102739B (zh) | 2005-01-12 | 2017-02-08 | 比奥根Ma公司 | 运输干扰素‑β的方法 |
| EP1909838A2 (en) * | 2005-07-29 | 2008-04-16 | Amgen Inc. | Formulations that inhibit protein aggregation |
| WO2007127668A2 (en) * | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| KR100785070B1 (ko) | 2006-07-11 | 2007-12-12 | 삼성전자주식회사 | 휴대 단말기에서 디지털 저작권 관리 콘텐츠 재생 방법 및장치 |
| US7951368B2 (en) | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| EA201070773A1 (ru) * | 2007-12-20 | 2010-12-30 | Мерк Сероно С. А. | Составы пэг-интерферона-бета |
| BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| PL2515941T3 (pl) | 2009-12-21 | 2020-04-30 | F. Hoffmann-La Roche Ag | Preparat farmaceutyczny zawierający bewacyzumab |
| US8802603B2 (en) | 2010-06-17 | 2014-08-12 | Becton, Dickinson And Company | Medical components having coated surfaces exhibiting low friction and low reactivity |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| FR2966044B1 (fr) * | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| ES2882063T3 (es) | 2012-12-03 | 2021-12-01 | Novobiotic Pharmaceuticals Llc | Nuevo depsipéptido y usos del mismo |
| WO2014158231A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2014159554A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
| ES2933549T3 (es) | 2013-07-10 | 2023-02-10 | Matrix Biology Inst | Composiciones de hialuronano con alta elasticidad y usos de las mismas |
| WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| BR112016010475B1 (pt) * | 2014-03-13 | 2021-07-20 | Stevanato Group International A.S. | Método de manuseio de uma formulação farmacêutica líquida |
| WO2016004197A1 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
| WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
| WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
| WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| CN108135926A (zh) | 2015-09-24 | 2018-06-08 | 基质生物研究所 | 高弹性透明质酸组合物及其使用方法 |
| WO2017147003A1 (en) | 2016-02-26 | 2017-08-31 | Novobiotic Pharmaceuticals, Llc | Novel macrocyclic antibiotics and uses thereof |
| FI126979B (en) | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
| ES2981759T3 (es) | 2017-04-04 | 2024-10-10 | Novobiotic Pharmaceuticals Llc | Nuevos depsipéptidos y sus usos |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| WO2022146917A1 (en) | 2020-12-28 | 2022-07-07 | Davol Inc. | Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2622598A (en) | 1951-03-08 | 1952-12-23 | Premo Pharmaceutical Lab Inc | Drain-clear container for aqueous liquid pharmaceutical preparations |
| US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| CA2133962C (en) * | 1992-05-06 | 2005-02-08 | Robert G. Wolfangel | Container and closure system for maintaining stability of sodium hypochlorite solutions |
| US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW249202B (es) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| PT862452E (pt) | 1995-11-07 | 2004-04-30 | Genentech Inc | Formulacao de estabilizacao para o ngf |
| US6142977A (en) | 1996-10-18 | 2000-11-07 | Schering Ag | Prefilled, sterilized syringe with a new and improved plug |
| NZ336548A (en) * | 1996-12-24 | 2001-09-28 | Biogen Inc | Stable liquid interferon formulations comprising an amino acid as the stabilising agent |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CN2326243Y (zh) * | 1997-09-29 | 1999-06-30 | 程继勇 | 覆膜药用瓶塞 |
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| CN2441750Y (zh) * | 2000-06-23 | 2001-08-08 | 程继勇 | 表面覆膜药用橡胶瓶塞 |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| CN1133565C (zh) * | 2001-10-18 | 2004-01-07 | 郑秀娣 | 药品瓶塞隔离膜 |
-
2004
- 2004-05-11 AR ARP040101607 patent/AR044302A1/es not_active Application Discontinuation
- 2004-05-12 PL PL04760770T patent/PL1633388T3/pl unknown
- 2004-05-12 WO PCT/EP2004/050779 patent/WO2004100979A2/en not_active Ceased
- 2004-05-12 BR BRPI0410679 patent/BRPI0410679A/pt not_active IP Right Cessation
- 2004-05-12 UA UAA200510442A patent/UA91493C2/uk unknown
- 2004-05-12 JP JP2006530185A patent/JP2007502684A/ja not_active Withdrawn
- 2004-05-12 HR HRP20140267TT patent/HRP20140267T1/hr unknown
- 2004-05-12 EP EP04760770.0A patent/EP1633388B1/en not_active Expired - Lifetime
- 2004-05-12 SI SI200432149T patent/SI1633388T1/sl unknown
- 2004-05-12 US US13/151,459 patent/USRE43331E1/en not_active Expired - Lifetime
- 2004-05-12 KR KR20057021160A patent/KR101084412B1/ko not_active Expired - Fee Related
- 2004-05-12 PT PT04760770T patent/PT1633388E/pt unknown
- 2004-05-12 DK DK04760770T patent/DK1633388T3/da active
- 2004-05-12 AU AU2004237982A patent/AU2004237982C1/en not_active Expired
- 2004-05-12 MX MXPA05012191A patent/MXPA05012191A/es active IP Right Grant
- 2004-05-12 US US10/556,467 patent/US7540382B2/en not_active Ceased
- 2004-05-12 ES ES04760770.0T patent/ES2471942T3/es not_active Expired - Lifetime
- 2004-05-12 CA CA 2523477 patent/CA2523477A1/en not_active Withdrawn
- 2004-05-12 EP EP20110152658 patent/EP2324845A1/en not_active Withdrawn
- 2004-05-12 EA EA200501692A patent/EA008308B1/ru not_active IP Right Cessation
- 2004-05-12 CN CN2004800169917A patent/CN1809376B/zh not_active Expired - Lifetime
-
2005
- 2005-11-13 IL IL17191205A patent/IL171912A/en active IP Right Grant
- 2005-12-06 NO NO20055774A patent/NO20055774D0/no not_active Application Discontinuation
-
2012
- 2012-01-13 JP JP2012005485A patent/JP2012096063A/ja active Pending
-
2014
- 2014-05-30 CY CY20141100386T patent/CY1115233T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044302A1 (es) | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos | |
| AR092919A2 (es) | Composicion farmaceutica liquida | |
| ES2273078T3 (es) | Suspension farmaceutica inyectable en un vial con dos camaras. | |
| BR0100554A (pt) | Dispositivo de acondicionamento e de aplicação que possui uma estrutura porosa que incorpora um agente biocida | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| JP2007502684A5 (es) | ||
| BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
| AR043144A1 (es) | Formulacion de inmunoglobulina y metodo de preparacion de la misma | |
| BRPI0410488B8 (pt) | Composição farmacêutica líquida estabilizada e livre de hsa, método para preparação de composição farmacêutica líquida estabilizada e livre de hsa, e recipiente vedado hermeticamente | |
| BR0311877A (pt) | Preparações ácidas de insulina com estabilidade aperfeiçoada | |
| BRPI0412241A (pt) | formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa) | |
| CL2003002767A1 (es) | Composicion oral que comprende una pelicula que contiene un material funcional, en un vehiculo, util para el cuidado oral. | |
| CL2010000816A1 (es) | Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06) | |
| DK1197221T3 (da) | Langtidsstabiliserede G-CSF-præparater | |
| DE69912262D1 (de) | Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln | |
| DE60126433D1 (de) | Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen | |
| EA200400148A1 (ru) | Стабилизированная суспензионная лекарственная форма для перорального применения | |
| MXPA05008138A (es) | Composiciones orales de fenretinida que tienen biodisponibilidad incrementada y metodos de uso de las mismas. | |
| WO2003007868A8 (en) | Storage of liquid compositions | |
| BR0312782A (pt) | Composição para o tratamento de manchas | |
| PE3096A1 (es) | Formulacion conteniendo selenio | |
| AR023274A1 (es) | Dispositivo de distribucion de una composicion con gradiente de concentracion | |
| AR037131A1 (es) | Formulaciones de jarabe de ribavirina | |
| ES2191930T3 (es) | Composicion desinfectante a base de acido peracetico y de un agente tensioactivo no ionico. | |
| ITMI20022549A1 (it) | Composizione quaternaria comprendente come sostanza attiva la propolis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |